HUP0401292A2 - Pirazolo[1,5-a] piridinek, ezeket tartalmazó gyógyszerkészítmények és eljárás ezek előállítására - Google Patents

Pirazolo[1,5-a] piridinek, ezeket tartalmazó gyógyszerkészítmények és eljárás ezek előállítására

Info

Publication number
HUP0401292A2
HUP0401292A2 HU0401292A HUP0401292A HUP0401292A2 HU P0401292 A2 HUP0401292 A2 HU P0401292A2 HU 0401292 A HU0401292 A HU 0401292A HU P0401292 A HUP0401292 A HU P0401292A HU P0401292 A2 HUP0401292 A2 HU P0401292A2
Authority
HU
Hungary
Prior art keywords
group
membered
carbon
carbon atoms
membered heteroaryl
Prior art date
Application number
HU0401292A
Other languages
English (en)
Inventor
Shigeki Hibi
Koichi Kikuchi
Yorihisa Hoshino
Motohiro Soejima
Tatsuya Yoshiuchi
Kogyoku Shin
Mutsuko Ono
Yoshinori Takahashi
Hisashi Shibata
Mitsuhiro Ino
Tetsuya Hirakawa
Original Assignee
Eisai Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co. Ltd. filed Critical Eisai Co. Ltd.
Publication of HUP0401292A2 publication Critical patent/HUP0401292A2/hu
Publication of HUP0401292A3 publication Critical patent/HUP0401292A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)

Abstract

A találmány olyan (I) általános képletű új vegyületekre vonatkozik,amelyek kortikotropin releasing faktor (CRF) receptort antagonizálóaktivitással rendelkeznek, valamint ezek sóira és hidrátjaira, és ezentúlmenően eljárásra a vegyületek előállítására és ezek gyógyszerkénttörténő alkalmazására. Az (I) általános képletben Rl jelentése példáulhidrogénatom, halogénatom, nitro-, cianocsoport vagy 1-10 szénatomosalkoxi-, 1-10 szénatomos alkilcsoport stb. R2, R3 és R4 jelentéseegymástól függetlenül hidrogénatom, halogénatom, ciano-, nitro-,hidroxil-, 6-14 szénatomos aril-, 5-14-tagú heteroarilcsoport stb.vagy R2 és R3 vagy R3 és R4 jelentése együtt 5-7 tagú gyűrű; R5 és R6jelentése egymástól függetlenül -X5-X6-X' általános képletű csoport,ahol a képletben X5 jelentése egyes kötés vagy -CO-; X6 jelentéseegyes kötés, -NR3a-, oxigénatom, kénatom, szulfinil-, szulfonil-, 1-10szénatomos alkilén-, 2-10 szénatomos alkenilén vagy 2-10 szénatomos,alkiniléncsoport és X7 és R3a jelentése egymástól függetlenül,hidrogénatom, 1-10 szénatomos alkil-, 2-10 szénatomos alkenil-, 2-10szénatomos alkinil-, 3-8 szénatomos cikloalkil-, 5-8 szénatomoscikloalkenil-, 6-14 szénatomos aril-, 5-14 tagú heteroarilcsoport, 4-14 tagú heterociklus, 9-11-tagú benzollal kondenzált gyűrűs csoport,8-11 tagú kondenzált heteroarilcsoport vagy biciklusos 7-12 tagúgyűrűs szénhidrogéncsoport; Ar jelentése 6-14 szénatomos arilcsoport,5-14 tagú heteroarilcsoport, 9-11 tagú benzollal kondenzált gyűrűscsoport vagy 8-11 tagú heteroaril kondenzált csoport. A vegyületekalkalmasak a kortikotropin releasing faktorral (CRF) összefüggőbetegségek kezelésére vagy megelőzésére, a betegség például lehet:depresszió, mánia, szorongás, pánikbetegség, fóbiák, stressz okoztagyomor-bél rendellenességek, cyclothymia, skizofrénia, gyomorfekély,irritábilis bélszindróma, fekélyes vastagbélgyulladás, hasmenés,székrekedés, dementia, neurodegeneratív betegségek, táplálkozásirendellenességek, pharmacophilia, drogelvonással járó tünetek,szklerózis, glaukóma, autonóm egyensúlyzavar, hajhullás, neurózis,magas vérnyomás, szív-érrendszeri betegségek, gyulladásos betegségek,fájdalom, allergózis. Ó
HU0401292A 2001-04-27 2002-04-25 Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof HUP0401292A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001133207 2001-04-27
PCT/JP2002/004173 WO2002088121A1 (fr) 2001-04-27 2002-04-25 Pyrazolo[1,5-a] pyridines et medicaments les contenant

Publications (2)

Publication Number Publication Date
HUP0401292A2 true HUP0401292A2 (hu) 2004-12-28
HUP0401292A3 HUP0401292A3 (en) 2011-01-28

Family

ID=18981104

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401292A HUP0401292A3 (en) 2001-04-27 2002-04-25 Pyrazolo[1,5-a]pyridines, pharmaceutical compositions containing the same and process for preparation thereof

Country Status (21)

Country Link
US (3) US7091215B2 (hu)
EP (1) EP1389618B1 (hu)
JP (2) JP4206273B2 (hu)
KR (2) KR100876622B1 (hu)
CN (1) CN1290846C (hu)
AT (1) ATE512962T1 (hu)
AU (1) AU2002251546B2 (hu)
BR (1) BR0209252A (hu)
CA (1) CA2443802C (hu)
CZ (1) CZ301491B6 (hu)
ES (1) ES2366082T3 (hu)
HU (1) HUP0401292A3 (hu)
IL (2) IL158624A0 (hu)
MX (1) MXPA03009738A (hu)
NO (1) NO326783B1 (hu)
NZ (1) NZ529333A (hu)
PL (1) PL214231B1 (hu)
RU (1) RU2308457C2 (hu)
TW (1) TWI292760B (hu)
WO (1) WO2002088121A1 (hu)
ZA (1) ZA200308860B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
EP1389618B1 (en) 2001-04-27 2011-06-15 Eisai R&D Management Co., Ltd. Pyrazolo 1,5-a pyridines and medicines containing the same
CA2478715A1 (en) * 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
US7176216B2 (en) * 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
AU2003275589B2 (en) * 2002-10-22 2009-05-28 Eisai R & D Management Co., Ltd. 7-phenyl pyrazolopyridine compounds
DE10311300A1 (de) * 2003-03-14 2004-09-23 Bayer Cropscience Ag 2,4,6-Phenylsubstituierte cyclische Ketoenole
CN1942468B (zh) 2004-04-12 2011-06-22 卫材R&D管理有限公司 吡唑缩合环衍生物的制造方法
CN101253173A (zh) * 2005-09-02 2008-08-27 辉瑞有限公司 羟基取代的1h-咪唑并吡啶和方法
US7578855B2 (en) 2005-11-09 2009-08-25 L'ORéAL S.A. Composition for dyeing keratin fibers comprising at least one cationic 3-amino-pyrazolopyridine derivative, and methods of use thereof
US7635394B2 (en) * 2005-11-09 2009-12-22 L'oreal S.A. Composition for the dyeing of keratin fibers comprising at least one 3-amino-pyrazolopyridine derivatives
FR2893027B1 (fr) * 2005-11-09 2010-12-17 Oreal Composition pour la teinture des fibres keratiniques comprenant au moins un derive 3-amino pyazolopyridine cationique
FR2892924B1 (fr) * 2005-11-09 2008-01-18 Oreal Composition pour la teinture des fibres keratiniques comprenant au moins un derive 3-amino pyrazolopyridine
EA018036B1 (ru) * 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
CA2682925A1 (en) * 2007-04-10 2008-10-16 David C. Ihle Heteroaryl amide analogues
FR2915879B1 (fr) * 2007-05-09 2009-07-03 Oreal Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier
FR2915880B1 (fr) * 2007-05-09 2009-07-03 Oreal Procede de coloration des fibres keratiniques comprenant l'application d'une base d'oxydation aminopyrazolopyridine en l'absence d'agent oxydant
EP2231662B1 (en) * 2007-12-19 2011-06-22 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
CA2721670C (en) 2008-04-15 2013-09-10 Eisai R&D Management Co., Ltd. 3-phenylpyrazolo[5,1-b]thiazole compound
JP5371535B2 (ja) * 2009-04-24 2013-12-18 矢崎総業株式会社 クランプ、及び電子部品内蔵ユニット
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.
FR2950345B1 (fr) * 2009-09-18 2011-09-23 Sanofi Aventis Derives acetyleniques de 5-phenyl-pyrazolopyridine, leur preparation et leur application en therapeutique
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
WO2011043387A1 (ja) * 2009-10-08 2011-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
EP2757884B1 (en) 2011-09-22 2022-07-27 Merck Sharp & Dohme LLC Pyrazolopyridyl compounds as aldosterone synthase inhibitors
CA2898294C (en) * 2013-02-21 2020-06-09 Calitor Sciences, Llc Heteroaromatic compounds as pi3 kinase modulators
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011399B1 (hu) * 1970-12-17 1975-04-30
JPS5320360B2 (hu) * 1973-05-30 1978-06-26
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US5190862A (en) * 1987-04-01 1993-03-02 Boehringer Mannheim Gmbh Chromogenic compounds and the use thereof as enzyme substrates
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
DE3942357A1 (de) 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh 3-aminopyrazolo-heterocyclen, deren verwendung zur bestimmung von wasserstoffperoxid, wasserstoffperoxid-bildenden systemen, peroxidase, peroxidatisch wirksamen substanzen oder von elektronenreichen aromatischen verbindungen, entsprechende bestimmungsverfahren und hierfuer geeignete mittel
DE3942356A1 (de) 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh Verwendung von 1-arylsemicarbaziden zur stabilisierung von enzymsubstraten, entsprechende verfahren und diagnostisches mittel enthaltend einen solchen stabilisator
DE3942355A1 (de) * 1989-12-21 1991-06-27 Boehringer Mannheim Gmbh N- und o-substituierte aminophenolderivate, zwischenprodukte zu deren herstellung, deren verwendung als hydrolasesubstrate, ein entsprechendes bestimmungsverfahren und hierfuer geeignetes diagnostisches mittel
EP0497258B1 (en) 1991-01-29 2002-01-02 Fujisawa Pharmaceutical Co., Ltd. Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer
JPH051063A (ja) * 1991-06-24 1993-01-08 Kyorin Pharmaceut Co Ltd ピラゾロピリジン誘導体及びその製造法
JPH0568913A (ja) 1991-09-11 1993-03-23 Yoshikazu Yui 生ゴミの自動脱水封入装置
FR2687675B1 (fr) * 1992-01-31 1997-04-18 Roussel Uclaf Nouveaux derives bicycliques de la pyridine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
ATE177426T1 (de) * 1992-06-17 1999-03-15 Upjohn Co Pyrridino-, pyrrolidino- und azepino- substituierte oxime als antiatherosklerosemittel und antihypercholesterolemiemittel
JPH0616667A (ja) * 1992-07-01 1994-01-25 Kyorin Pharmaceut Co Ltd ピラゾロ［１，５−ａピリジン誘導体の新規製造方法
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
EP0959074A3 (en) 1992-12-17 2000-06-07 Pfizer Inc. Substituted pyrazoles as CRF antagonists
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
KR0170567B1 (ko) 1992-12-17 1999-02-18 알렌 제이. 스피겔 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘
FR2701708B1 (fr) 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
DE4311460A1 (de) 1993-04-08 1994-10-13 Boehringer Mannheim Gmbh Verfahren zur kolorimetrischen Bestimmung eines Analyten mittels Benzylalkoholdehydrogenase und einem chromogenen Redoxindikator
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
FR2714059B1 (fr) 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
PL181895B1 (pl) 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
US5701900A (en) 1995-05-01 1997-12-30 Cedars-Sinai Medical Center Ultrasonic transducer orientation sensing and display apparatus and method
EP0882051B1 (en) 1996-02-07 2001-11-07 Janssen Pharmaceutica N.V. Thiophenopyrimidines
NZ330119A (en) 1996-02-07 2000-02-28 Janssen Pharmaceutica Nv Pyrazolopyrimidines as crf receptor antagonists
US6022978A (en) 1996-06-11 2000-02-08 Pfizer Inc. Benzimidazole derivatives
CN1227554A (zh) 1996-08-28 1999-09-01 辉瑞大药厂 取代的6,5－杂二环衍生物
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
BR9810508A (pt) 1997-07-03 2000-09-05 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento de uma desordem
EP0937081A1 (en) 1997-08-22 1999-08-25 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO 4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
FR2801308B1 (fr) * 1999-11-19 2003-05-09 Oreal COMPOSITIONS DE TEINTURE DE FIBRES KERATINIQUES CONTENANT DE DES 3-AMINO PYRAZOLO-[1,(-a]-PYRIDINES, PROCEDE DE TEINTURE, NOUVELLES 3-AMINO PYRAZOLO-[1,5-a]-PYRIDINES
EP1244666A1 (en) 1999-12-17 2002-10-02 Bristol-Myers Squibb Pharma Company Imidazopyrimidinyl and imidazopyridinyl derivatives
EP1301511A2 (en) 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
IL156813A0 (en) 2001-01-26 2004-02-08 Bristol Myers Squibb Co Imidazolyl derivatives and pharmaceutical compositions containing the same
FR2822692B1 (fr) * 2001-03-27 2005-01-28 Oreal Composition pour la teinture d'oxydation contenant au moins une base d'oxydation 3-amino pyrazolo-[1,5-a]-pyridine et au moins un coupleur aminophenol particulier
EP1389618B1 (en) 2001-04-27 2011-06-15 Eisai R&D Management Co., Ltd. Pyrazolo 1,5-a pyridines and medicines containing the same
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
CA2478715A1 (en) * 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
US7176216B2 (en) * 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds

Also Published As

Publication number Publication date
NO20034788D0 (no) 2003-10-24
TWI292760B (en) 2008-01-21
ATE512962T1 (de) 2011-07-15
KR20080031501A (ko) 2008-04-08
HUP0401292A3 (en) 2011-01-28
CN1290846C (zh) 2006-12-20
PL367067A1 (en) 2005-02-21
US20060217348A1 (en) 2006-09-28
US7091215B2 (en) 2006-08-15
CZ301491B6 (cs) 2010-03-24
KR100876622B1 (ko) 2008-12-31
WO2002088121A1 (fr) 2002-11-07
US7285666B2 (en) 2007-10-23
BR0209252A (pt) 2004-07-20
CN1505630A (zh) 2004-06-16
JP2009051843A (ja) 2009-03-12
AU2002251546B2 (en) 2007-01-18
CA2443802C (en) 2010-04-13
NO20034788L (no) 2003-12-29
US20040122039A1 (en) 2004-06-24
RU2003134371A (ru) 2005-06-27
EP1389618B1 (en) 2011-06-15
ES2366082T3 (es) 2011-10-17
EP1389618A4 (en) 2005-07-20
MXPA03009738A (es) 2004-01-29
NO326783B1 (no) 2009-02-16
KR100881647B1 (ko) 2009-02-04
RU2308457C2 (ru) 2007-10-20
EP1389618A1 (en) 2004-02-18
NZ529333A (en) 2005-01-28
IL158624A (en) 2011-04-28
CA2443802A1 (en) 2002-11-07
ZA200308860B (en) 2005-04-26
IL158624A0 (en) 2004-05-12
CZ20032937A3 (cs) 2004-03-17
US7625925B2 (en) 2009-12-01
PL214231B1 (pl) 2013-07-31
JPWO2002088121A1 (ja) 2004-08-19
US20070249663A1 (en) 2007-10-25
KR20040008163A (ko) 2004-01-28
JP4206273B2 (ja) 2009-01-07
JP4977668B2 (ja) 2012-07-18

Similar Documents

Publication Publication Date Title
HUP0401292A2 (hu) Pirazolo[1,5-a] piridinek, ezeket tartalmazó gyógyszerkészítmények és eljárás ezek előállítására
Granacher et al. Physostigmine: Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
Shi et al. Vasorelaxant effect of harman
HUP0401718A2 (hu) Biciklusos oxo-piridin- és oxo-pirimidin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
JP4246488B2 (ja) 化学化合物
JP2004500425A (ja) パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
JP2016527263A (ja) ブロモドメイン阻害剤としての新規キナゾリノン
MXPA06002618A (es) Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
TW201102387A (en) Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
HUP0105428A2 (hu) Aril vagy heteroaril-azolilkarbinol-származékok alkalmazása a P-anyag feleslege által közvetített rendellenességek kezelésére alkalmas gyógyszerkészítmények előállítására
KR950704320A (ko) Crf 길항제로서의 피롤로피리미딘(pyrrolopyrimidines as crf antagonists)
Goodman et al. Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy)
CA2582436A1 (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
JP2019532092A (ja) Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎアルファ応答の調節剤として有用なヘテロ二環化合物
JPH02292281A (ja) ３―ｎ置換カルバモイル―インドール誘導体
HUP0303721A2 (hu) Imidazolilszármazékok mint kortikotropin releasing faktor inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0303254A2 (hu) Új pirimidinvegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ITMI20000922A1 (it) Articoli di manifattura
Wells et al. Chemistry, pharmacology, pharmacokinetics, adverse effects, and efficacy of the antidepressant maprotiline hydrochloride
CA2477516C (en) Pharmaceutical formulation comprising melatonin
Moghadam et al. An approach to pharmacological targets of pyrrole family from medicinal chemistry viewpoint
TW201446243A (zh) 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
IL96260A (en) Pharmaceutical preparations containing derivatives and analogues of pyrimidone for the short-term treatment of skin diseases and infections
JP5039994B2 (ja) 睡眠障害の治療のためのミルタザピンの使用

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: EISAI R&D MANAGEMENT CO., LTD., JP

Free format text: FORMER OWNER(S): EISAI CO. LTD., JP

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished